BRCA1 and ovarian cancer: Furthermore, breast cancer patients with BRCA1/BRCA2-deficiency have recently been shown to benefit from PARP inhibitor treatment [9] which is well-known in ovarian cancer, where BRCA1/BRCA2 mutational status is routinely used for directing this treatment [29, 30].